Cour Pharmaceuticals set to advance CNP-106 for myasthenia gravis

Oct. 26, 2022

Cour Pharmaceuticals Inc. announced that the FDA has cleared an IND application to initiate a phase Ib/IIa proof-of-concept study of its...

BioWorld Science Immune Neurology/psychiatric FDA IND

Today's news in brief

BioWorld

BioWorld briefs for July 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 16, 2025.

Atai Therapeutics discovers new 5-HT2A receptor partial agonists

BioWorld Science

Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful...

PHD inhibitors reported in Akebia Therapeutics patent

BioWorld Science

Akebia Therapeutics Inc. has identified new derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate acting as prolyl 4-hydroxylase (PHD) inhibitors.

Woman in military clothing talking with psychologist

FDA wants more data for Otsuka’s sNDA in PTSD

BioWorld

The U.S. FDA is insisting that another study is needed to bolster the sNDA for Rexulti (brexpiprazole) from Otsuka Pharmaceutical Co. Ltd. in treating adults with...